Eli Lilly and Company (LLY) News Today

Eli Lilly and Company (NYSE: LLY) shares were under pressure as investors weighed legal action against unauthorized retatrutide sellers and recent insider sales against strong demand for Lilly’s obesity-drug portfolio and favorable analyst sentiment.

• Positive Sentiment: Lilly filed six lawsuits against U.S. companies allegedly selling black-market versions of experimental obesity drug retatrutide. The action could help protect patients, preserve the drug’s future commercial value and limit counterfeit competition ahead of potential regulatory approval. Lilly sues six companies over alleged illegal sales of retatrutide
• Positive Sentiment: Lilly’s oral GLP-1 obesity drug Foundayo received its first approval outside the United States in the United Kingdom. The decision expands Lilly’s addressable market and strengthens its position against Novo Nordisk, although initial availability will be primarily through private prescriptions while NHS coverage is reviewed. Eli Lilly takes weight-loss pill battle global
• Positive Sentiment: An analyst upgrade and higher valuation targets added support to the stock’s bullish narrative. Lilly’s latest quarter also showed revenue growth of 47.7% to $22.97 billion and EPS of $8.38, well above the $6.40 consensus estimate, with fiscal 2026 EPS guidance of $35.50 to $36.50. Eli Lilly trading higher following analyst upgrade
• Neutral Sentiment: The retatrutide lawsuits are strategically positive but could involve legal expenses and do not change the drug’s regulatory status. Retatrutide remains experimental and has not yet been approved for sale.
• Negative Sentiment: Chief Accounting Officer Donald Zakrowski sold 2,000 shares worth about $2.37 million, following an executive vice president’s $5.95 million sale. Both transactions were made under pre-arranged Rule 10b5-1 plans, reducing their importance as indicators of management confidence, but the sales may weigh modestly on sentiment. Lilly chief accounting officer insider sale
• Negative Sentiment: Erste Group Bank trimmed its 2026 EPS estimate to $34.93 from $35.34, below Lilly’s guidance range and consensus expectations. With the stock trading at an elevated earnings multiple near 41 times, investors may be sensitive to any signs of slower growth or more conservative forecasts. Eli Lilly analyst estimates